Syndax Pharmaceuticals (NASDAQ: SNDX) shares Q3 and six‑month 2025 results

Rhea-AI Filing Summary

Syndax Pharmaceuticals, Inc. filed a current report announcing that it released its financial results for the quarter and six months ended September 30, 2025. On November 3, 2025, the company issued a press release and a corporate presentation describing these results, which are included as Exhibits 99.1 and 99.2. The company notes that this earnings information is being furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.

Insights

Equity research analyst

Syndax furnished Q3 and six‑month 2025 results via press release and slide deck.

Syndax Pharmaceuticals released financial results for the quarter and six months ended September 30, 2025, using a press release and corporate presentation. This is a common approach that lets management pair numbers with narrative explanations, such as pipeline progress or expense trends, within a visual format.

The company explicitly designates this information as furnished, not filed, under the Exchange Act. That distinction limits how the data is treated for certain liability provisions and incorporation into other SEC documents unless specifically referenced. Investors looking for the actual revenue, expenses, or cash metrics would need to review Exhibits 99.1 and 99.2 that accompany this report.

0001395937false00013959372025-11-032025-11-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 03, 2025

SYNDAX PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37708	32-0162505
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
730 THIRD AVENUE FLOOR 9
NEW YORK, New York				10017
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 419-1400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		SNDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 3, 2025, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation announcing its financial results for the quarter and six months ended September 30, 2025. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

The information contained in this Item 2.02 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated November 3, 2025
99.2	Corporate Presentation, dated November 3, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNDAX PHARMACEUTICALS, INC.
	By:	/s/ Michael A. Metzger
		Michael A. Metzger
		Chief Executive Officer

Dated: November 3, 2025

FAQ

What did Syndax Pharmaceuticals (SNDX) disclose in this 8-K?

Syndax Pharmaceuticals disclosed that it issued a press release and a corporate presentation on November 3, 2025 announcing its financial results for the quarter and six months ended September 30, 2025.

Which periods do the reported Syndax Pharmaceuticals (SNDX) results cover?

The reported results cover the company’s financial performance for the quarter and six months ended September 30, 2025.

Where can investors find the detailed SNDX financial results mentioned in this filing?

The detailed results are contained in the press release and corporate presentation attached as Exhibits 99.1 and 99.2 to the report.

Are the Syndax Pharmaceuticals (SNDX) results considered filed or furnished with the SEC?

The company states that the information in Item 2.02 and Exhibits 99.1 and 99.2 is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities or automatically incorporated into other SEC filings unless specifically referenced.

Who signed this Syndax Pharmaceuticals (SNDX) 8-K?

The report was signed on behalf of Syndax Pharmaceuticals, Inc. by Michael A. Metzger, the company’s Chief Executive Officer.

What exhibits accompany this Syndax Pharmaceuticals (SNDX) 8-K?

The report includes a press release dated November 3, 2025 as Exhibit 99.1, a corporate presentation dated November 3, 2025 as Exhibit 99.2, and a cover page interactive data file as Exhibit 104.